Ensysce Biosciences, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how Ensysce Biosciences performed this year. My goal is to turn complex filing information into plain language so you can decide if this company fits your investment goals.

1. What does this company do?

Ensysce Biosciences is a research-focused pharmaceutical company based in La Jolla, California. They use two proprietary platforms: TAAP™ and MPAR™. These are designed to create pain medications that only activate when swallowed. This prevents misuse via injection or snorting and protects against accidental overdose.

Because they are in the "clinical-stage," they are still testing their products. They have earned $0 in sales because their lead candidates, PF614 and PF614-MPAR, have not yet received FDA approval.

2. Financial health: The "Burn" continues

To be blunt, Ensysce is not yet profitable. For 2023, the company reported a $20.2 million loss, compared to a $17.5 million loss in 2022. Most of this spending went toward $13.5 million in research and development.

As of late 2023, the company had about $1.5 million in cash. They spent roughly $1.2 million per month to keep operations running. Because they aren't making money yet, they rely on outside funding to stay afloat.

3. Major wins and challenges

The biggest story this year was the company’s constant need for cash. They have used several methods to raise money:

• Warrant Inducements: The company encouraged investors to exercise their stock options early by lowering the price. This brings in quick cash but often lowers the stock price.
• Direct Offerings: They sold stock and warrants directly to institutional investors to raise $5 million in early 2024.

This keeps the lights on, but it comes at a cost. Every time they issue new shares to raise money, your "slice of the pie" gets smaller. This is called dilution. In 2023, the number of shares increased significantly, which reduces the potential value for long-term shareholders.

4. Key risks: What could hurt the stock?

Because this is a high-risk, research-focused company, keep these red flags in mind:

• Clinical Trial Success: The company’s value rests on two products. If their Phase 3 trials fail or the FDA demands more studies, the company’s value could collapse.
• Funding Dependency: With very little cash, the company risks running out of money. Their financial statements include a "going concern" warning, meaning they may not have enough cash to last the next 12 months without raising more.
• Nasdaq Compliance: The stock has struggled to stay above the $1.00 minimum price required by Nasdaq. If they don't regain compliance, they could be moved to the OTC markets, making the stock harder to trade.
• Intellectual Property: Their business depends on patents that expire between 2027 and 2039. If they cannot defend these patents or if new non-opioid therapies replace their technology, their future revenue could disappear.

5. Future outlook

The company is focused on finishing the PF614 Phase 3 clinical trials. Their future depends on successful test results and managing their cash without exhausting shareholders through constant dilution. They are a "bet" on whether their technology will become the new standard for safe pain management.

---

Final thought for your decision: Investing in a clinical-stage company like Ensysce is essentially betting on the success of their upcoming trial results. Before deciding, ask yourself if you are comfortable with the high risk of dilution and the company's current need to secure more funding to survive the next year.